Skip to main content
OpenTrials
Completed

NCT Number: NCT03405285

Connected Catheter Clinical Feasibility Study( CFS)

The objective of this study is to evaluate the safety and essential performance of the Connected Catheter System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting, and during and extended period (up to 29 days) of home use.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

West Coast Urology, 11411 Brookshire Avenue, Suite 508, Downey, California, United States

Loading trial locations.

About this study

The Connected Catheter (C2P) is a replaceable urinary prosthesis that is intended for use in male patients 18 years of age or older who have impaired bladder emptying due to neurogenic lower urinary tract dysfunction, and who are capable of operating the device in accordance with the provided instructions for use, or who have trained caregivers capable of doing the same. The device must be replaced every 29 days

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males age ≥ 18 with clinical diagnosis of neurogenic lower urinary tract dysfunction (NLUTD)
  • Must be clinically suitable and capable of safely managing bladder using an intermittent voiding strategy Must have stable urinary management history with clean intermittent catheterization: no significant changes in bladder management regimen within past 12 months

OR:

Must have urodynamic profile suitable for CIC, as assessed via urodynamics study within past 12 months (including bladder capacity > 200mL without uninhibited bladder contractions)

  • Subject's lower urinary tract anatomy (lengths of proximal and distal urethral must fall within the ranges serviceable by the Connected Catheter device, as specified in the investigational device instructions for use.
  • For cases of NLUTD due to spinal cord injury, the subject must be in medically stable condition (i.e. post-spinal shock phase)

Exclusion criteria

  • Active symptomatic urinary tract infection, as defined in this protocol (subjects may receive the CoCath Device after UTI has been treated)
  • Significant risk profile or recent history of urethral stricture (e.g. stricture within past 90 days)
  • Significant risk profile or recent history of clinically significant autonomic dysreflexia (e.g. History of hospitalization due to AD within past 12 months)
  • Significant intermittent urinary incontinence (between catheterizations)
  • Uninhibited bladder contractions and/or vesico-ureteral reflux that is not reliably controlled with medication or alternate therapy (e.g. botox injections)
  • Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy, urine analysis, and blood labs)
  • Urinary tract inflammation or neoplasm
  • Urinary fistula
  • Bladder diverticulum (outpouching) > 5cm in size
  • Chronic pyelonephritis (secondary to upper urinary tract infection(s) within past 6 months)
  • Impaired kidney function or renal failure (assessed via blood creatinine levels > 2 mg/dL)
  • Active gross hematuria
  • Active urethritis
  • Bladder stones
  • Dependence on an electro-magnetic medical implant (e.g. cardiac pacemaker or implanted drug pump) or external device
  • Individuals allergic or otherwise unable to take oral antibiotics
  • Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the CoCath System

Treatment and study plan

Connected Catheter

Device

The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.

Primary outcomes

  1. Freedom from genito-urinary injury/trauma

    Time frame: 29 Days

    Improved bladder management without injury or trauma to genito-urinary tract

  2. Successful Acute Performance- I

    Time frame: On the day of Connected Catheter Insertion

    To evaluate successful retention of Connected Catheter and Void

  3. Successful Acute Performance -II

    Time frame: On the day of Connected Catheter Insertion

    To evaluate successful bladder voiding with Connected Catheter

  4. Successful Acute Performance- III

    Time frame: On the day of Connected Catheter Insertion

    To evaluate successful removal of Connected Catheter

  5. Successful Acute Performance- IV

    Time frame: On the day of Connected Catheter Insertion

    To evaluate successful post-void sealing of Connected Catheter Valve

  6. Successful Home-Use Performance

    Time frame: 29 days

    Successful Home-Use using same measures as Acute Performance

Sponsors and collaborators

Lead sponsor

Spinal Singularity

Industry

Registry information

Official study title

Clinical Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jan 23, 2018
Registry last updated
Sep 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.